MFN2 and pulmonary arterial hypertension: In vivo overexpression of Mfn2, through airway nebulization of an adenoviral Mfn2 vector, regresses PAH in the chronic hypoxia–SU5416 PAH model in female rats, as judged by improved treadmill walking distance, decreased pulmonary vascular resistance and decreased PA medial thickness.